GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM

NCT07314684 on ClinicalTrials.gov · last registry update 2026-01-02

Recruiting now, toward 80 participants. Due to report 8 March 2027. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: RECRUITING
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Federico II University
Sponsor type: Other
Enrollment: 80
Started: 2025-09-08
Primary completion: 2027-03-08 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

To evaluate the effects of semaglutide in addition to standard therapy on inflammatory biomarkers compared with standard therapy alone in T2DM patients without ASCVD or severe TOD but with SCORE2-Diabetes ≥10%.

Conditions studied

T2DM (Type 2 Diabetes Mellitus)

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.